You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205081 - 205090 of 207714 results
  1. Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling


    PROJECT SUMMARY Zika virus, until recently an obscure mosquito-borne flavivirus from Africa, emerged rapidly in 2015-2016 to pose a major threat to public health in the Western Hemisphere. Having traveled across the Pacific, it quickly became endemic in South and Central America, Mexico and the Caribbean, carried by a compatible Aedes mosquito vector population. While Zika virus infection is typic ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Dual View Endoscopy for Colonoscopy

    SBC: OMNISCIENT IMAGING INC            Topic: 102

    AbstractAn estimatedmillion colonoscopies are performed annually in the US at a cost of about $Bhowever current colonoscopes with forward vision fail to detectof precancerous polypsOverof the missed polyps are located on or behind numerous folds in the colon where they are hidden from the sight of a forward view colonoscopeIn this research proposalwe propose to complete our development of an imagi ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Preventing outbreaks of foodborne pathogenic bacteria in edible sprouts via novel resistance-conferring seed treatments

    SBC: Ascribe Bioscience Inc.            Topic: NIAID

    Abstract Ascribe Bioscience is developing a novel technology to prevent foodborne outbreaks caused by the consumption of edible sprouts. Sprouts are highly vulnerable to infection with human enteric bacterial pathogens at the seed stage. These pathogens then grow exponentially in the warm and humid conditions used for sprouting. Even low initial bacterial counts on seeds can result in unsafe micro ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  4. A Proton Tomography System for Optimization of Proton Therapy

    SBC: ProtonVDA LLC            Topic: NCI

    Abstract Proton therapy is rapidly expanding in the United States. Currently, the calculation of proton range in proton therapy patients is based on a conversion of CT Hounsfield Units of patient tissues to proton relative stopping power. Uncertainties in this conversion necessitate larger proximal and distal planned target volume margins. These larger margins increase the dose to nearby healthy t ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Near patient molecular diagnostics test for infections

    SBC: GeneFluidics, Inc.            Topic: R

    ABSTRACT Currently there are no FDA cleared molecular based tests for urinary tract infection UTI pathogen identification and antimicrobial susceptibility testing to replace the andapos gold standardandapos of dipstick urinalysis and urine culturing All pathogen identification tests still rely on clinical isolates from urine cultures largely unchanged from Kochandapos s postulates developed ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: NEURODON, LLC            Topic: NIA

    Neurodon LLC proposes to conduct lead optimization and candidate-seeking activities on a novel series of neuroprotective small molecules that shows efficacy in a transgenic model of Alzheimer’s disease (AD). AD is a leading cause of death in the United States, with some estimates ranking it as high as third behind cardiovascular disease and cancer. Despite the enormity of this national public he ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Vaccine Strategies for Candidal Infections

    SBC: NOVADIGM THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Candida species are opportunistic fungal pathogens that have become among the most common causes of nosocomial infections in the United States and worldwide. Disseminated infections caused by Candida spp. have increased 15-fold in incidence in the last 15 years, and Candida is now the third most common cause of bloodstream infections. Even with modern antifunga ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  8. Innovative and Modular Open System Radar Algorithm Test Environment

    SBC: NUMERICA CORPORATION            Topic: MDA14005

    MDA invests millions annually on new radar technologies. However, because it is often difficult to relate theoretical advances to warfighter advantages, MDA is challenged to determine the value of certain investments. A critical need is an evaluation tool that can assess early-development radar algorithms, using consistent metrics, so that promising investments can be quickly differentiated from l ...

    SBIR Phase II 2016 Department of DefenseMissile Defense Agency
  9. Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer

    SBC: Medical Guidance Systems LLC            Topic: 102

    The proposed developmental activity will result in a humanized monoclonal antibody, Tiptuhumab, which acts as a radiomodulator/immunotherapeutic. This antibody targets the cancer neoantigen, Tax Interacting Protein-1 (TIP-1), and is cytotoxic to non-small-cell lung cancer cells, NSCLC. For patients with NSCLC, the 5-year overall survival rate is 14.9% with a median survival time of 4 months. The c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. N/A


    Not Available A new design approach is proposed for partial communication liquid acquisition devices (LADs) with window screens for cryogenic applications. These "start-basket" devices differ from total communication devices in that liquid is retained in an auxiliary

    SBIR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government